DUBLIN – Autolus Ltd. closed an $80 million series C round, the largest private equity deal in European biotech this year, to progress its clinical pipeline of autologous chimeric antigen receptor (CAR) T-cell therapies in hematological malignancies. The London-based immuno-oncology firm also plans to allocate some of the cash to its preclinical pipeline of therapies that address solid tumor indications.